Merck’s Zilovertamab Vedotin + R-CHP Shows 100% Complete Response in Phase 2 DLBCL Trial
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has presented promising results from its Phase 2 waveLINE-007 trial at the 66th American Society of Hematology (ASH) Annual Meeting. The trial evaluated zilovertamab vedotin, an investigational antibody-drug…
ReAlta Life Sciences Presents Positive Preclinical Data for RLS-0071 in aGVHD at ASH Annual Meeting
ReAlta Life Sciences, Inc. (“ReAlta”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, announced promising preclinical data for its lead asset, RLS-0071 (pegtarazimod), in acute Graft-versus-Host Disease (aGVHD). These findings will…
Epcoritamab Combination Therapy Shows High Response Rates in R/R Follicular Lymphoma
Genmab A/S has shared new results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab (R2) for treating relapsed or refractory (R/R) follicular lymphoma (FL). The study demonstrated an…
Orca Bio Presents Clinical Results of Orca-Q® Without GvHD Prophylaxis at ASH 2024
Orca Bio, a late-stage biotechnology company focused on transforming patient care through high-precision cell therapy, presented clinical findings today at the 66th American Society of Hematology (ASH) Annual Meeting. The data highlights the use of Orca-Q, its investigational second-generation allogeneic…
New Results Show Donor Search Score Equalizes Transplant Outcomes at ASH 2024
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will present new findings at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. The data demonstrates that a donor search prognosis score enables physicians to expedite…
IMFINZI® (durvalumab) Receives US Priority Review for Muscle-Invasive Bladder Cancer
AstraZeneca has announced that its supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted by the U.S. Food and Drug Administration (FDA) for Priority Review. This application aims to expand the treatment options for patients with muscle-invasive bladder…
Children’s Hospital LA Marks 100th Retinal Gene Therapy Procedure
Aaron Nagiel, MD, PhD, a leading pediatric retinal specialist at Children’s Hospital Los Angeles (CHLA), often hears stories from parents long after their child’s retinal gene therapy treatment. These heartfelt updates highlight significant improvements, such as a toddler seeing animals…
Alithea Genomics Unveils Full-Length DRUG-Seq for Enhanced Drug Discovery
Alithea Genomics, a leader in RNA sequencing and transcriptomics, has introduced its MERCURIUS™ Full-Length DRUG-seq library preparation technology. This groundbreaking innovation combines massive sample multiplexing, an extraction-free workflow, and full transcript coverage, creating a unique RNA-seq workflow. The technology is…
Innate Pharma and IFLI Announce Up to $7.9M Investment for IPH6501 Development in Follicular Lymphoma
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and the Institute for Follicular Lymphoma Innovation (IFLI) have entered into a strategic partnership to investigate the potential of IPH6501, Innate’s anti-CD20 ANKET® (Antibody-based NK cell Engager Therapeutics), in the treatment of…
Datopotamab Deruxtecan Shows Promise in EGFR-Mutated NSCLC
A pooled analysis of the TROPION-Lung05 phase 2 and TROPION-Lung01 phase 3 trials demonstrated that datopotamab deruxtecan (Dato-DXd) achieved significant clinical responses in patients with previously treated advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). These findings, including progression-free…
Pfizer Highlights Leadership in Breast Cancer and Blood Disorders at ASH and SABCS
Pfizer Inc. (NYSE: PFE) is set to showcase significant advancements in its hematology and breast cancer portfolios at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December…
UGN-102 Shows Promising Long-Term Results in Phase 3 ENVISION Trial for LG-IR-NMIBC
UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing innovative treatments for urothelial and specialty cancers, has announced the presentation of the Phase 3 ENVISION trial’s efficacy and safety results at the Society of Urologic Oncology (SUO) annual…